Physician profile
Pulla Reddy
NPI 1437167962
$3,027.90
in general payments reported to CMS, 2019-2025
16 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $71.98 · 2021: $78.53 · 2022: $208 · 2023: $398 · 2024: $164 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,305.81 | 2019-2022 | |
| Abbott Laboratories | $316.16 | 2020-2025 | Cardiomems |
| Cvrx, INC. | $266.87 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.44 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $191.38 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $137.80 | 2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $118.51 | 2019-2025 | Eliquis |
| Impulse Dynamics (USA) INC. | $118.46 | 2022-2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $118.17 | 2025 | Amvuttra |
| Edwards Lifesciences Corporation | $55.20 | 2022-2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $49.24 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $33.70 | 2019 | |
| Amarin Pharma, INC. | $26.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $14.70 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.63 | 2025 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pulla Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.